Premium
Seven percent hypertonic saline—0.1% hyaluronic acid in infants with mild‐to‐moderate bronchiolitis
Author(s) -
Nenna Raffaella,
Papoff Paola,
Moretti Corrado,
De Angelis Daniela,
Battaglia Massimo,
Papasso Stefano,
Bernabucci Mariangela,
Cangiano Giulia,
Petrarca Laura,
Salvadei Serena,
Nicolai Ambra,
Ferrara Marianna,
Bonci Enea,
Midulla Fabio
Publication year - 2014
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.22935
Subject(s) - medicine , bronchiolitis , hypertonic saline , inhalation , saline , logistic regression , anesthesia , pediatrics , respiratory system
Summary Objectives Our study was aimed to evaluate the efficacy of 7% hypertonic saline and 0.1% hyaluronic acid (7% HS–HA) given by inhalation, in infants hospitalized for mild‐to‐moderate bronchiolitis. Methods In a double‐blind controlled study, 39 infants (23 boys) <7 months of age (median age 2 months) were enrolled and randomly assigned to receive either nebulized 7% HS–HA (7%NaCl + 0.1%HA) (n:21) or 0.9 normal saline (NS) (n:18) at a dose of 2.5 ml twice a day for 3 days. All infants were assigned a clinical severity score at admission and four times daily during hospitalization. Main outcome measures were number of days hospitalization, safety and daily reduction in the severity score. Results No difference was found between the two groups for clinical severity score at admission. One child in the study group and two in the NS group interrupted the study protocol; 19% of infants in the study group and 11% in the NS group had mild cough after the aerosol. The length of stay in the control group and treatment groups were 4.8 ± 1.5 versus 4.1 ± 1.9 days, respectively ( P = 0.09). There was a trend for shortening the hospitalization days in the treatment group by 14.6%. The use of NS in the control group was identified as an independent risk factor for length of hospital stay using the multivariate logistic regression model ( P = 0.04). No difference was observed between the two groups for the clinical score reduction during the first 3 days hospitalization. Conclusions 7% HS–HA is a safe and effective therapy in treating infants hospitalized for mild‐to‐moderate bronchiolitis. Pediatr Pulmonol. 2014; 49:919–925. © 2013 Wiley Periodicals, Inc.